Liver endothelial cells in NAFLD and transition to NASH and HCC
Abstract Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of metabolic syndrome, which is characterised by obesity, insulin resistance, hypercholesterolemia and hypertension. NAFLD is the most frequent liver disease worldwide and more than 10% of NAFLD patients progress to the inflammatory and fibrotic stage of non-alcoholic steatohepatitis (NASH), which can lead to end-stage liver disease including hepatocellular carcinoma (HCC), the most frequent primary malignant liver tumor. Liver sinusoidal endothelial cells (LSEC) are strategically positioned at the interface between blood and hepatic parenchyma. LSECs are highly specialized cells, characterised by the presence of transcellular pores, called fenestrae, and exhibit anti-inflammatory and anti-fibrotic characteristics under physiological conditions. However, during NAFLD development they undergo capillarisation and acquire a phenotype similar to vascular endothelial cells, actively promoting all pathophysiological aspects of NAFLD, including steatosis, inflammation, and fibrosis. LSEC dysfunction is critical for the progression to NASH and HCC while restoring LSEC homeostasis appears to be a promising approach to prevent NAFLD progression and its complications and even reverse tissue damage. In this review we present current information on the role of LSEC throughout the progressive phases of NAFLD, summarising in vitro and in vivo experimental evidence and data from human studies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Cellular and molecular life sciences - 80(2023), 11 vom: 05. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Velliou, Rallia-Iliana [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Hepatocellular carcinoma |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00018-023-04966-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053308166 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053308166 | ||
| 003 | DE-627 | ||
| 005 | 20231112064626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231006s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00018-023-04966-7 |2 doi | |
| 035 | |a (DE-627)SPR053308166 | ||
| 035 | |a (SPR)s00018-023-04966-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Velliou, Rallia-Iliana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liver endothelial cells in NAFLD and transition to NASH and HCC |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of metabolic syndrome, which is characterised by obesity, insulin resistance, hypercholesterolemia and hypertension. NAFLD is the most frequent liver disease worldwide and more than 10% of NAFLD patients progress to the inflammatory and fibrotic stage of non-alcoholic steatohepatitis (NASH), which can lead to end-stage liver disease including hepatocellular carcinoma (HCC), the most frequent primary malignant liver tumor. Liver sinusoidal endothelial cells (LSEC) are strategically positioned at the interface between blood and hepatic parenchyma. LSECs are highly specialized cells, characterised by the presence of transcellular pores, called fenestrae, and exhibit anti-inflammatory and anti-fibrotic characteristics under physiological conditions. However, during NAFLD development they undergo capillarisation and acquire a phenotype similar to vascular endothelial cells, actively promoting all pathophysiological aspects of NAFLD, including steatosis, inflammation, and fibrosis. LSEC dysfunction is critical for the progression to NASH and HCC while restoring LSEC homeostasis appears to be a promising approach to prevent NAFLD progression and its complications and even reverse tissue damage. In this review we present current information on the role of LSEC throughout the progressive phases of NAFLD, summarising in vitro and in vivo experimental evidence and data from human studies. | ||
| 650 | 4 | |a Liver |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sinusoidal endothelial cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-alcoholic fatty liver disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-alcoholic steatohepatitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatocellular carcinoma |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Legaki, Aigli-Ioanna |4 aut | |
| 700 | 1 | |a Nikolakopoulou, Polyxeni |4 aut | |
| 700 | 1 | |a Vlachogiannis, Nikolaos I. |4 aut | |
| 700 | 1 | |a Chatzigeorgiou, Antonios |0 (orcid)0000-0002-7039-4223 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular and molecular life sciences |d Cham (ZG) : Springer International Publishing AG, 1997 |g 80(2023), 11 vom: 05. Okt. |w (DE-627)SPR00008039X |w (DE-600)1458497-9 |x 1420-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2023 |g number:11 |g day:05 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00018-023-04966-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2023 |e 11 |b 05 |c 10 | ||